RxDoctor Payments Data

Bruce Benedick, MD

Cardiovascular Disease · E Palo Alto, CANPI 1346274602

Payments from drug & device makers

$4,172in general payments, 2019–2025

Across 193 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$618
  • E.r. Squibb & Sons, L.L.C.$375
  • Boehringer Ingelheim$347
  • Johnson & Johnson$333
  • Pfizer$315
  • Sanofi-aventis U.S. LLC$286
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$3,98796%
  • Education$1864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,172 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,080,497
Medicare patients
1,846
Services billed
7,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban630$937,040
JardianceEmpagliflozin529$790,532
EntrestoSacubitril/Valsartan169$279,632
Repatha SureclickEvolocumab101$137,257
MultaqDronedarone Hcl39$66,679
XareltoRivaroxaban47$62,068
Praluent PenAlirocumab51$48,740
Ezetimibe807$31,918
VascepaIcosapent Ethyl19$16,612
Atorvastatin Calcium1,395$15,840
Losartan Potassium1,369$15,151
FarxigaDapagliflozin Propanediol11$12,987
Rosuvastatin Calcium412$7,984
Carvedilol499$7,087
Amlodipine Besylate814$5,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$937,040630 claims
Boehringer IngelheimJardiance$347$790,532529 claims
NovartisEntresto$167$279,632169 claims
Sanofi-aventis U.S. LLCMultaq$286$66,67939 claims
Johnson & JohnsonXarelto$333$62,06847 claims
AstraZenecaFarxiga$221$12,98711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in E Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →